Class information for:
Level 1: INSULIN GLARGINE//INSULIN DETEMIR//BIPHASIC INSULIN ASPART 30

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1497 2538 33.5 77%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
79 26608 DIABETES CARE//DIABETES EDUCATOR//DIABETES TECHNOLOGY & THERAPEUTICS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INSULIN GLARGINE Author keyword 194 62% 8% 199
2 INSULIN DETEMIR Author keyword 154 81% 4% 93
3 BIPHASIC INSULIN ASPART 30 Author keyword 116 97% 1% 33
4 BASAL INSULIN Author keyword 85 67% 3% 76
5 PREMIXED INSULIN Author keyword 59 90% 1% 26
6 INSULIN DEGLUDEC Author keyword 56 81% 1% 34
7 NPH INSULIN Author keyword 56 69% 2% 48
8 INSULIN INITIATION Author keyword 50 84% 1% 27
9 BIPHASIC INSULIN ASPART Author keyword 42 78% 1% 28
10 DETEMIR Author keyword 31 63% 1% 31

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 INSULIN GLARGINE 194 62% 8% 199 Search INSULIN+GLARGINE Search INSULIN+GLARGINE
2 INSULIN DETEMIR 154 81% 4% 93 Search INSULIN+DETEMIR Search INSULIN+DETEMIR
3 BIPHASIC INSULIN ASPART 30 116 97% 1% 33 Search BIPHASIC+INSULIN+ASPART+30 Search BIPHASIC+INSULIN+ASPART+30
4 BASAL INSULIN 85 67% 3% 76 Search BASAL+INSULIN Search BASAL+INSULIN
5 PREMIXED INSULIN 59 90% 1% 26 Search PREMIXED+INSULIN Search PREMIXED+INSULIN
6 INSULIN DEGLUDEC 56 81% 1% 34 Search INSULIN+DEGLUDEC Search INSULIN+DEGLUDEC
7 NPH INSULIN 56 69% 2% 48 Search NPH+INSULIN Search NPH+INSULIN
8 INSULIN INITIATION 50 84% 1% 27 Search INSULIN+INITIATION Search INSULIN+INITIATION
9 BIPHASIC INSULIN ASPART 42 78% 1% 28 Search BIPHASIC+INSULIN+ASPART Search BIPHASIC+INSULIN+ASPART
10 DETEMIR 31 63% 1% 31 Search DETEMIR Search DETEMIR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NPH INSULIN 365 54% 18% 469
2 TO TARGET TRIAL 311 78% 8% 208
3 GLARGINE 213 49% 12% 315
4 BASAL INSULIN 195 53% 10% 259
5 BASAL BOLUS REGIMEN 185 85% 4% 97
6 GLUCOSE LOWERING DRUGS 133 84% 3% 73
7 BLOOD GLUCOSE CONTROL 104 20% 18% 458
8 DETEMIR 90 61% 4% 97
9 BOLUS TREATMENT 90 88% 2% 43
10 PROTAMINE HAGEDORN INSULIN 67 80% 2% 41

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PRIMARY CARE DIABETES 3 11% 1% 26

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Basal insulin analogues in the management of diabetes mellitus: what progress have we made? 2014 12 71 82%
Insulin Therapy for Type 2 Diabetes Mellitus 2014 12 87 68%
Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies 2007 84 62 90%
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations 2011 154 41 24%
Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus Systematic Review and Meta-analysis 2012 45 17 76%
Refining basal insulin therapy: what have we learned in the age of analogues? 2007 48 48 94%
Insulin degludec: overview of a novel ultra long-acting basal insulin 2013 10 27 85%
Stepwise intensification of insulin therapy in Type2 diabetes managementexploring the concept of the basal-plus approach in clinical practice 2013 10 34 82%
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance 2014 5 39 82%
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus 2007 65 36 69%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CIPTO MANGUNKUSOMO HOSP 9 83% 0.2% 5
2 DIABETOL METAB ENDOCRINOL 5 63% 0.2% 5
3 STUDY PROF HANEFELD 5 55% 0.2% 6
4 SECT INTERNAL MED ENDOCRINOL METAB 5 44% 0.3% 8
5 ELEANOR JOSEPH KOSOW DIABET TREATMENT 4 75% 0.1% 3
6 DIABET PLATFORM TEAM 3 100% 0.1% 3
7 GLOBAL METAB 3 100% 0.1% 3
8 INSULIN CLIN PHARMACOL 3 100% 0.1% 3
9 DIABET TRIALS UNIT 3 15% 0.7% 19
10 CELLULAR MED DIABET 3 38% 0.2% 6

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000208406 INTERMITTENT GLUCOSE//POSTPRANDIAL HYPERGLYCEMIA//GLYCEMIC VARIABILITY
2 0.0000174481 INSULIN PEN//FLEXPEN//VIAL AND SYRINGE
3 0.0000174312 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION//CSII//INSULIN PUMP
4 0.0000156023 CORE DIABETES MODEL//DIABETES RELATED COMPLICATIONS//ROYAL NEW ZEALAND GEN PRACTITIONERS UNIT
5 0.0000130972 IDOP//DIABET OLDER PEOPLE IDOP//ADMINISTRATIVE HEALTH CARE UTILIZATION DATA
6 0.0000127587 CHRONIC CARE MODEL//PACIC//DIABETES CARE
7 0.0000105271 DPP 4 INHIBITOR//SITAGLIPTIN//VILDAGLIPTIN
8 0.0000105054 PIOGLITAZONE//ROSIGLITAZONE//THIAZOLIDINEDIONES
9 0.0000101042 HYPOGLYCAEMIA UNAWARENESS//COUNTERREGULATION//HYPOGLYCAEMIA
10 0.0000093044 NATEGLINIDE//KAD 1229//REPAGLINIDE